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Reduced endothelin-1– and nitric oxide–mediated arteriolar
tone in hypertensive renal transplant recipients.
Background. The prevalence of hypertension is high in
renal transplant recipients. It has been suggested that cal-
cineurin inhibitors (CI) contribute to the development of
post-transplant hypertension by stimulating endothelin (ET-1)-
mediated and/or reducing nitric oxide (NO)-mediated vascular
tone.
Methods. We tested this hypothesis using 2 groups of renal
transplant recipients [normotensive patients without a need
for antihypertensive medication (Normo-Tx), and hyperten-
sive patients requiring antihypertensives (Hyper-Tx)] in the
presence of CI-based immunosuppression. In addition, we
studied matched control subjects (C). BQ 123 (ET-A recep-
tor antagonist), BQ123 + BQ788 (ET-A/B-receptor antago-
nist), ET-1, L-NMMA (NO-synthase inhibitor), acetylcholine
(ACH; endothelium-dependent vasodilator), glyceroltrinitrate
(GTN, NO donor), and norepinephrine (NE, endothelium-
independent vasoconstrictor) were infused into the brachial
artery. Forearm blood flow (FBF) was measured by venous oc-
clusion plethysmography.
Results. Endothelium-independent vasomotion in response
to GTN and NE was similar in all groups. Vascular responses
to selective and combined blockade of ET receptors in both
Normo-Tx and Hyper-Tx did not exceed those of C. In fact, we
observed a significantly lower increase in FBF after BQ 123 (P =
0.03), as well as after BQ 123/788 (P = 0.03) in Hyper-Tx com-
pared with Normo-Tx. This was associated with an increased
vascular sensitivity to exogenous ET-1 in Hyper-Tx compared
with Normo-Tx (P = 0.04). Vasoconstriction after L-NMMA
was reduced in Hyper-Tx compared with Normo-Tx (P =0.015),
while the response to ACH was reduced in both groups of Tx
patients to a similar degree (P = 0.005 vs. C).
Conclusion. Our results do not support a major role for the
vascular endothelin system in the hypertension of renal trans-
plant recipients, whereas deficient baseline NO production may
be a contributing factor.
Hypertension is a frequent abnormality in kidney
transplant recipients. Hypertension is also a known risk
factor for cardiovascular mortality and for renal trans-
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plant survival [1]. The causes of this hypertension are not
fully understood. It has been proposed that the recipient’s
own kidneys, the blood pressure of the donor, glucocor-
ticoid medication, calcineurin inhibitors (CI), and other
factors are involved. Calcineurin inhibitors are known to
stimulate the generation of endothelin-1 (ET-1) in vitro
and in vivo [2, 3]. Several lines of evidence suggest that
ET-1 plays a pivotal role in post-transplant hypertension
[4–6]. In addition, it was reported that calcineurin in-
hibitors may interfere with nitric oxide (NO)-mediated
vascular relaxation [7–9].
We were therefore interested in the question if in-
creased vascular ET-1 and/or reduced nitric oxide could
be shown to participate in post-transplant hypertension–
associated vascular dysfunction in patients. We tested the
functional state of the vascular endothelin and NO sys-
tem in vivo in renal allograft recipients with hyperten-
sion and matched healthy control subjects. We studied
arterial resistance vessels of the forearm circulation, a
representative vascular bed for testing blood pressure
regulation. We asked the following specific questions: (1)
is there evidence for a general increase in ET-1 mediated
arteriolar tone in Tx patients with calcineurin inhibitor-
based immunosuppression? and (2) is there an imbalance
between ET-1– and NO-mediated vascular tone specifi-
cally in those Tx patients who require antihypertensive
medication?
We used intrabrachial infusions of selective (ET-A re-
ceptor), as well as of unselective (ET-A/B) endothelin
receptor antagonism. We also tested the vascular effects
of ET-1 itself. Furthermore, we measured the arteriolar
responses to blockade of NO synthases (NOS), as well
as to stimulation of endothelial NOS (eNOS). Finally,
we determined endothelium-independent vasoconstric-
tion and vasodilation.
METHODS
Subjects
The study was approved by the institutional review
board of our hospital. All participants gave written in-
formed consent.
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Renal transplant recipients who received calcineurin
inhibitors and had excellent graft function were included.
Only patients whose transplantation had been performed
more than 12 months ago were included in the stud-
ies. Patients with diseases potentially interfering with
endothelial function (diabetes mellitus, congestive heart
failure, liver cirrhosis, manifested vascular diseases) were
excluded. All patients were nonsmokers. Tx patients
were divided into two groups: (1) patients with normal
blood pressure (Normo-Tx) not requiring antihyperten-
sive medication. The normotensive state was verified by
24-hour blood pressure recording; (2) patients with hy-
pertension. These patients were taking at least two differ-
ent antihypertensive agents for adequate blood pressure
control (Hyper-Tx). Patients of both groups (Normo-Tx,
Hyper-Tx) were selected in such a way that they were
matched for age, gender, height, body weight, and serum
cholesterol, as well as for the intake of statins and the
type of calcineurin inhibitor used [cyclosporine A (CSA)
or tacrolimus (FK)].
Control subjects were asked for their past medical his-
tory and received a physical examination.
In Tx patients studies were performed during the first
four hours after the intake of their morning dose of
calcineurin inhibitor. In the Hyper-Tx group antihyper-
tensive medication was withdrawn before the studies.
Patients were instructed to take a final dose of antihyper-
tensive drugs 36 hours before each experimental session.
This relatively short washout period was chosen because
the different protocols of infusion were separated by
7 days only. A longer period of discontinuation of an-
tihypertensives appeared to be inappropriate for ethical
reasons. All participants were asked to refrain from large
meals and from beverages containing alcohol or caffeine
during 6 hours before the start of each protocol.
Technique
Studies were performed in a quiet, temperature-
controlled room (23 to 25◦C) with the subjects resting
supine. In control subjects the brachial artery of the non-
dominant arm (in Tx patients the arm without the arterio-
venous fistula) was cannulated by a 27G steel needle
(Cooper Needleworks, Birmingham, UK) for drug in-
fusion. Forearm blood flow (FBF) was measured by a
calibrated venous occlusion plethysmograph (Gutmann
Medizinelektronik, Eurasburg, Germany), as described
previously [10]. The pressure of the upper arm-congesting
cuff was set to 40 mm Hg. During the measurements the
circulation of the hand was occluded by a wrist cuff in-
flated to 220 mm Hg. FBF was measured for 10 seconds
in each 15-second cycle.
Infusion protocols
The complete study consisted of four infusion protocols
that were conducted on separate days at least 7 days apart.
After cannulation of the brachial artery a resting period
of 20 minutes was allowed before at least two baseline
FBF recordings were obtained. All infusions were given
at a constant rate of 1 mL/min.
Protocol 1. BQ 123 (ET-A receptor antagonist) was
infused at 40 nmol/min for 60 minutes. FBF readings were
obtained every 10 minutes.
Protocol 2. BQ 123 at 40 nmol/min was infused together
with BQ 788 (ET-B receptor antagonist) at 50 nmol/min
for 60 minutes. FBF was recorded every 10 minutes.
Protocol 3. Norepinephrine (NE) was infused in 3 in-
creasing doses (60, 120, and 240 nmol/min, each dose for
5 min). FBF was recorded during the last 2.5 minutes of
each infusion period. After 30 minutes of saline infusion
ET-1 at 5 pmol/min was given for 60 minutes. FBF read-
ings were performed every 10 minutes.
Protocol 4. Venous blood was drawn for determina-
tion of plasma levels of ET-1. Acetylcholine (ACH)
was infused in 3 increasing doses (55, 110, and 220
nmol/min; each dose over 5 min). After a resting period
of 30 minutes N-monomethyl-L-arginine (L-NMMA) was
given at 1, 2, and 4 lmol/min. Another resting period of
30 minutes was followed by infusion of GTN at 2.2, 4.4,
and 8.8 nmol/min. FBF was recorded during the last 2.5
minutes of each period of drug infusion.
Drugs and agents
All solutions of drugs and agents were prepared fresh
before each protocol with isotonic saline to obtain the re-
quired concentrations. Drugs and agents were obtained
as follows: BQ 123, BQ 788, ET-1, and L-NMMA from
Clinalfa (La¨ufelfingen, Switzerland); ACH as Miochol-
E from Ciba Vision (Germering, Germany); GTN as
Perlinganit (Schwarz Pharma, Monheim, Germany);
and NE as Arterenol (Aventis, Frankfurt, Germany).
Calculations and statistics
A determination of FBF consisted of 10 repetitive in-
dividual measurements of FBF, and was calculated as the
mean of the last 5 measurements. Data are expressed as
the percent change from baseline FBF (with baseline set
to 0%) ± standard error of mean (SEM) as calculated by
the formula:
FBF (% change) = [(FBF observed/baseline FBF) ×
100] − 100.
Comparisons between groups were performed by two-
way analysis of variance (ANOVA) for repeated mea-
surements with the computer software Statistical Package
for the Social Sciences (SPSS) version 10.0.1 (Chicago, IL,
USA). A P < 0.05 was considered significant.
RESULTS
The studies were tolerated well by all participants.
There were no side effects from arterial puncture or drug
infusion. We enrolled a total of 20 renal transplant re-
cipients (9 Normo-Tx and 11 Hyper-Tx) and 30 healthy
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Table 1. Group characteristics
Characteristic Control Normo-Tx Hyper-Tx P value (Normo-Tx vs. Hyper-Tx)
Protocol 1 N 18 8 10
Male/female 15/3 6/2 7/3
Age years 33 ± 2 36 ± 4 42 ± 3 0.22
Height cm 175 ± 2 171 ± 4 174 ± 3 0.58
Weight kg 71 ± 3 71 ± 4 76 ± 3 0.27
Blood pressure mm Hg
Systolic 120 ± 1 126 ± 2 148 ± 3 <0.0001
Diastolic 75 ± 2 78 ± 2 90 ± 3 <0.0001
Cholesterol mmol/L 4.8 ± 0.1 5.0 ± 0.2 5.1 ± 0.2 0.75
Creatinine lmol/L 76 ± 6 133 ± 10 130 ± 8 0.52
CSA/FK 4/4 5/5
Statins N = 2 N = 4
Protocol 2 N 15 8 9
Male/female 13/2 6/2 6/3
Age years 33 ± 2 36 ± 4 43 ± 3 0.11
Height cm 176 ± 3 171 ± 4 174 ± 3 0.54
Weight kg 72 ± 3 71 ± 4 78 ± 3 0.21
Blood pressure mm Hg
Systolic 121 ± 2 125 ± 3 151 ± 4 <0.0001
Diastolic 75 ± 2 79 ± 1 89 ± 2 <0.0001
Cholesterol mmol/L 4.8 ± 0.5 5.0 ± 0.7 5.2 ± 0.7 0.73
Creatinine lmol/L 78 ± 7 136 ± 11 131 ± 8 0.65
CSA/FK 4/4 4/4
Statins N = 2 N = 4
Protocol 3 N 11 8 8
Male/female 8/3 6/2 5/3
Age years 40 ± 4 36 ± 4 44 ± 3 0.09
Height cm 172 ± 2 171 ± 4 173 ± 3 0.71
Weight kg 70 ± 4 71 ± 4 79 ± 3 0.11
Blood pressure mm Hg
Systolic 120 ± 3 126 ± 2 153 ± 4 <0.0001
Diastolic 75 ± 2 77 ± 2 87 ± 2 <0.0001
Cholesterol mmol/L 4.9 ± 0.2 5.0 ± 0.2 5.3 ± 0.2 0.52
Creatinine lmol/L 73 ± 5 130 ± 11 128 ± 9 0.61
CSA/FK 4/4 5/3
Statins N = 2 N = 4
Protocol 4 N 10 9 7
Male/female 5/3 5/4 5/2
Age years 39 ± 4 40 ± 5 41 ± 5 0.87
Height cm 169 ± 3 167 ± 2 172 ± 3 0.18
Weight kg 66 ± 4 68 ± 4 76 ± 4 0.18
Blood pressure mm Hg
Systolic 123 ± 3 124 ± 2 149 ± 4 <0.0001
Diastolic 77 ± 2 73 ± 2 87 ± 2 <0.0001
Cholesterol mmol/L 5.0 ± 0.1 5.0 ± 0.3 5.1 ± 0.2 0.68
Creatinine lmol/L 78 ± 4 136 ± 12 129 ± 7 0.72
CSA/FK 5/4 5/2
Statins N = 3 N = 4
CSA, cyclosporin A; FK, tacrolimus.
control subjects. Not all participants completed all four
protocols. Therefore, the baseline characteristics of study
patients and control subjects are given separately for each
protocol in Table 1. Patients of the Hyper-Tx group had
the following antihypertensive medication: b-blockers
(N = 11), diuretics (N = 5), calcium antagonists (N =
8), sympatholytic agents (N = 5), angiotensin-converting
enzyme inhibitors (N = 2), and angiotensin II receptor
antagonists (N = 1).
Plasma levels of ET-1 were measured once in all par-
ticipants in protocol 4. They were significantly elevated
in Tx patients (6.5 ± 0.4 pmol/L in Normo-Tx and 7.9 ±
1.4 in Hyper-Tx) compared with control subjects (4.0 ±
0.3; P = 0.005 C vs. Normo-Tx, P = 0.63 Normo-Tx vs.
Hyper-Tx).
Protocol 1 (C: N = 18, Normo-Tx: N = 8, Hyper-
Tx: N = 10). Infusions of BQ 123 resulted in a time-
dependent increase in FBF in all groups. Vascular
responses of Hyper-Tx were significantly reduced com-
pared with Normo-Tx (P = 0.03) (Table 2, Fig. 1A), while
those in C and Normo-Tx were comparable.
Protocol 2 (C: N = 15, Normo-Tx: N = 8, Hyper-Tx:
N = 9). Combined blockade of both ET-A and ET-B re-
ceptors significantly increased FBF in all groups. Within
all groups the magnitude of this change in FBF tended to
be more pronounced than with ET-A receptor blockade
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Table 2. FBF data in absolute values (mL/dL × min) and in percent change from baseline (baseline = 0%) of all experimental protocols
P value
Normo-Tx
FBF Control % Normo-Tx % Hyper-Tx % vs. Hyper-Tx
Protocol 1 Baseline 2.5 ± 0.3 0 2.7 ± 0.3 0 3.0 ± 0.6 0 0.67
BQ123 10` 2.8 ± 0.3 16 ± 5 3.3 ± 0.4 19 ± 6 3.3 ± 0.9 3 ± 6
20` 3.0 ± 0.4 23 ± 11 3.9 ± 0.5 48 ± 12 3.4 ± 0.9 3 ± 7 0.03
30` 3.4 ± 0.5 41 ± 13 4.3 ± 0.5 60 ± 15 3.6 ± 1.0 9 ± 9 ANOVA
40` 3.8 ± 0.5 52 ± 14 4.4 ± 0.7 57 ± 19 3.9 ± 1.0 18 ± 11
50` 3.9 ± 0.5 60 ± 17 4.5 ± 0.7 65 ± 20 3.8 ± 1.0 15 ± 10
60` 4.2 ± 0.6 74 ± 23 4.3 ± 0.8 56 ± 22 3.8 ± 1.0 12 ± 12
Protocol 2 Baseline 2.4 ± 0.3 0 2.7 ± 0.5 0 2.7 ± 0.5 0 0.96
BQ123/788 10` 2.8 ± 0.4 18 ± 11 3.6 ± 0.6 32 ± 7 3.2 ± 0.6 17 ± 9
20` 3.3 ± 0.5 45 ± 14 3.9 ± 0.7 45 ± 10 3.4 ± 0.7 22 ± 9 0.03
30` 3.8 ± 0.5 63 ± 21 4.6 ± 0.8 73 ± 9 3.8 ± 1.0 31 ± 17 ANOVA
40` 4.2 ± 0.6 89 ± 24 5.0 ± 0.9 85 ± 13 3.9 ± 1.0 36 ± 16
50` 4.7 ± 0.6 114 ± 32 5.0 ± 0.9 91 ± 15 3.8 ± 1.0 35 ± 15
60` 4.8 ± 0.6 115 ± 26 4.8 ± 0.9 81 ± 21 3.9 ± 1.1 35 ± 19
Protocol 3 Baseline 2.4 ± 0.2 0 3.2 ± 0.3 0 3.3 ± 0.6 0 0.92
NE 60 pmol/min 1.9 ± 0.2 −20 ± 3 2.5 ± 0.3 −24 ± 3 2.7 ± 0.5 −19 ± 5
120 pmol/min 1.8 ± 0.3 −28 ± 5 2.3 ± 0.4 −32 ± 7 2.2 ± 0.4 −35 ± 5 0.68
240 pmol/min 1.5 ± 0.2 −39 ± 6 1.8 ± 0.3 −43 ± 5 1.9 ± 0.4 −43 ± 7 ANOVA
Baseline 2.8 ± 0.4 0 3.3 ± 0.4 0 3.0 ± 0.6 0 0.743
ET-1 10` 2.6 ± 0.3 −6 ± 6 3.0 ± 0.4 −6 ± 6 2.3 ± 0.5 −27 ± 7
20` 2.3 ± 0.2 −16 ± 6 2.8 ± 0.4 −11 ± 8 2.2 ± 0.5 −32 ± 8 0.04
30` 2.2 ± 0.2 −18 ± 7 2.9 ± 0.4 −8 ± 9 2.1 ± 0.4 −32 ± 8 ANOVA
40` 2.0 ± 0.2 −28 ± 6 2.5 ± 0.4 −23 ± 6 2.0 ± 0.4 −34 ± 6
50` 1.8 ± 0.2 −31 ± 6 2.7 ± 0.5 −16 ± 10 1.9 ± 0.4 −40 ± 8
60` 1.6 ± 0.2 −41 ± 4 2.6 ± 0.5 −24 ± 10 1.8 ± 0.4 −43 ± 9
Protocol 4 Baseline 2.4 ± 0.2 0 1.8 ± 0.3 0 3.1 ± 0.8 0 0.18
ACH 55 nmol/min 10.9 ± 1.3 344 ± 60 6.3 ± 1.0 302 ± 73 8.6 ± 1.6 258 ± 71 0.005a
110 nmol/min 15.0 ± 2.2 506 ± 83 7.2 ± 0.9 368 ± 78 11.4 ± 2.0 413 ± 132 ANOVA
220 nmol/min 21.4 ± 3.2 784 ± 108 8.4 ± 1.1 459 ± 107 11.8 ± 2.1 388 ± 118
Baseline 3.5 ± 0.4 0 2.4 ± 0.4 0 3.0 ± 0.6 0 0.47
L-NMMA 1 lmol/min 2.8 ± 0.4 −21 ± 5 1.8 ± 0.3 −26 ± 3 2.5 ± 0.8 −16 ± 6 0.015
2 lmol/min 2.3 ± 0.4 −37 ± 5 1.5 ± 0.2 −39 ± 4 2.2 ± 0.7 −28 ± 7 ANOVA
4 lmol/min 1.7 ± 0.2 −52 ± 4 1.0 ± 0.2 −55 ± 4 2.0 ± 0.6 −34 ± 3
Baseline 2.3 ± 0.3 0 1.7 ± 0.2 0 2.5 ± 0.8 0 0.39
GTN 2.2 nmol/min 4.1 ± 0.6 92 ± 21 3.1 ± 0.3 86 ± 11 4.8 ± 1.2 130 ± 28 0.23
4.4 nmol/min 5.6 ± 0.7 156 ± 26 3.8 ± 0.5 130 ± 18 5.8 ± 1.5 181 ± 38 ANOVA
8.8 nmol/min 7.5 ± 0.8 245 ± 30 4.9 ± 0.8 186 ± 24 7.0 ± 1.7 253 ± 58
Statistical comparisons are focused on differences between Normo-Tx and Tx HBP, and include those of baseline FBF values before each protocol (in mL/dL × min
by t test), as well as comparisons of experimental data within each protocol (in % change from baseline by ANOVA for repeated measurements).
aControl vs. Normo-Tx.
alone, although the differences did not reach significance.
The increase in FBF was significantly less in Hyper-Tx
compared with Normo-Tx (P = 0.03) (Table 2, Fig. 1B).
Protocol 3 (C: N = 11, Normo-Tx: N = 8, Hyper-Tx:
N = 8). Infusion of NE reduced FBF in all groups in a
comparable manner (Table 2, Fig. 3B).
Infusion of ET-1 was followed by a time-dependent
decrease of FBF in all participants. The reduction in FBF
was significantly less in Normo-Tx compared with Hyper-
Tx (P = 0.04) (Table 2, Fig. 1C).
Protocol 4 (C: N = 10, Normo-Tx: N = 9, Hyper-Tx:
N = 7). ACH increased FBF in a dose-dependent man-
ner. The increase in FBF was comparable in Normo-Tx
and Hyper-Tx, but significantly reduced compared with
C (P = 0.005 C vs. Normo-Tx) (Table 2, Fig. 2B).
L-NMMA dose-dependently reduced FBF in all
groups. The decrease in FBF was significantly less in
Hyper-Tx compared with Normo-Tx (P = 0.015) (Table 2,
Fig. 2A).
GTN increased FBF in all groups comparably (Table 2,
Fig. 3A).
In all participants who completed both protocol 2 and
protocol 3 we calculated the ratio of ET-1–mediated vas-
cular tone (individual maximum effect of unselective ET-
receptor blockade) to ET receptor sensitivity (individual
maximum effect of ET-1 itself) as an estimate of effective
endogenous ET-1 production (Fig. 4). In Hyper-Tx effec-
tive ET-1 production was significantly reduced compared
with Normo-Tx (P = 0.015).
To examine the individual balance between ET-1–
and NO-mediated vascular tone in both groups of re-
nal transplant recipients we created a scatter plot of
the maximum effects of combined ET receptor block-
ade versus the maximum effects of NO synthase inhi-
bition in all subjects having completed protocols 2 and
4 (Fig. 5). Data of the control group are not shown
because only four subjects completed both protocols 2
and 4.
1786 Passauer et al: Endothelin in post-transplant hypertension
0
20
40
60
80
100
FB
F,
 
%
 c
ha
ng
e
0 20 40 60
BQ 123, minutes
Normo-Tx (N = 8)
Hyper-Tx (N = 10)
C (N = 18)A
–60
–40
–20
0
FB
F,
 
%
 c
ha
ng
e
0 20 40 60
ET-1, minutes
Normo-Tx (N = 8)
Hyper-Tx (N = 8)
C (N = 11)
C
0
50
100
150
0 20 40 60
BQ 123/788, minutes
Normo-Tx (N = 8)
Hyper-Tx (N = 9)
C (N = 15)B
Fig. 1. Forearm blood flow (FBF) (% change
from baseline, baseline = 0%) in response
to intrabrachial infusions of (A) BQ 123 (40
nmol/min), (B) BQ 123/788 (40/50 nmol/min),
and (C) endothelin-1 (ET-1 5 pmol/min) in
control subjects (C), as well as normoten-
sive (Normo-Tx) and hypertensive (Hyper-
Tx) renal transplant recipients. Statistical
differences between Normo-Tx and Hyper-Tx
are shown. ∗P < 0.05.
–60
–40
–20
0
FB
F,
 
%
 c
ha
ng
e Normo-Tx (N = 9)
Hyper-Tx (N = 7)
C (N = 10) Normo-Tx (N = 9)
Hyper-Tx (N = 7)
C (N = 10)
A
0 2 4
L-NMMA, µmol/min ACH, nmol/min
0
500
1000
0 100 200
B
Fig. 2. (A) Baseline endothelial nitric oxide
generation was assessed by graded infusions
of L-NMMA (1, 2, and 4 lmol/min). (B)
Endothelium-dependent vasodilation in re-
sponse to acetylcholine (ACh, 55, 110, and 220
nmol/min). ∗P < 0.05.
DISCUSSION
This study was designed to describe the functional state
of the vascular ET—and NO—systems in renal transplant
recipients maintained on a calcineurin inhibitor–based
immunosuppressive regimen. Before discussing our main
results, comments on the role of ET in the regulation of
vascular tone in healthy subjects, as well as on method-
ologic aspects of our study may be appropriate.
In the literature there is prevailing consensus that en-
dogenous ET-1 mediates a basal vasoconstrictor tone in
healthy humans [11, 12]. ET-A receptors located on vas-
cular smooth muscle cells mediate a major part of the con-
strictor properties of ET-1. Endothelial ET-B receptors
mediate vasodilation via NO, whereas ET-B receptors lo-
cated on smooth muscle cells cause vasoconstriction. In
addition, the ET-B receptor acts as a clearance recep-
tor for ET-1. Selective blockade of ET-B may thus result
in an increased binding of ET-1 to ET-A receptors. We
therefore combined ET-A and ET-B receptor blockade
and did not perform experiments with selective blockade
of ET-B receptors.
Currently conflicting results exist about the hemody-
namic net effect of ET-B receptor blockade in healthy
subjects. This may be related to different doses of BQ 788
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Fig. 4. Estimation of effective vascular endothelin-1 (ET-1) production
in the forearm based on functional data. The ratio between the individ-
ual maxima of ET-1 mediated vascular tone (response to BQ 123 +
788) and ET-1 sensitivity (response to ET-1 itself, absolute values) was
calculated for control (N = 6), Normo-Tx(N = 8), and Hyper-Tx(N =
8). ∗P = 0.015 Normo-Tx vs. Hyper-Tx.
used. In the study of Verhaar et al [11] the net effect of
ET-B blockade by BQ 788 at 1 nmol/min was vaso-
constriction. This dose had been adopted from hand
vein experiments. Based on pharmacologic consideration
Cardillo et al [13] proposed a 50-fold higher dose of BQ
788 for forearm blood flow studies. We have recently
shown that this high dose of BQ 788 further enhances
vasodilation elicited by complete inhibition of ET-A re-
ceptors, indicating a role for ET-B receptors located
on myocytes, which are possibly not inhibited by low-
dose BQ 788 (discussed in detail in [14]). Because up-
regulation of ET-B on myocytes may play a role in Tx
patients we kept the dose of BQ 788 at 50 nmol/min for
the present study.
Undoubtedly, bilateral plethysmography is the prefer-
able method for testing the influence of drugs and me-
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Fig. 5. Individual balance of nitric oxide (NO)- and endothelin (ET)-
1–mediated vascular tone in renal transplant recipients. In Hyper-Tx,
contribution of both NO and ET-1 to baseline vascular tone is reduced
compared with Normo-Tx. Error bars represent mean ± SD.
diators on forearm blood flow [15–17]. However, all Tx
patients enrolled in our studies had patent arteriovenous
fistulas on one arm, which makes bilateral plethysmogra-
phy impossible. In the control group we used the two-arm
approach. Comparison between bilateral and unilateral
plethysmography within this group revealed no signifi-
cant differences between both methods (data not shown).
In view of the constancy of blood pressure and heart rate
throughout the experiments it is unlikely that systemic
effects of the drugs infused biased our results.
Several studies demonstrated in vitro that calcineurin
inhibitors are able to increase endothelial ET-1 produc-
tion [3]. In our study plasma levels of ET-1 were signif-
icantly elevated in Tx patients compared with control
subjects, which is in line with previous reports [2]. How-
ever, one major result is that in Tx patients the vascu-
lar ET system is not overactive compared with matched
control subjects. This is primarily shown by the fact that
vascular responses to both selective and unselective ET
receptor blockade in either group of Tx patients exceeded
that of control subjects (Fig. 1A and B). In this way
our results support the broadly accepted view that ET-1
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plasma concentrations do not reflect ET-1–mediated vas-
cular tone [14, 18–20]. Published data suggest that the
elevated ET-1 plasma concentrations of Tx patients are
unable to cause significant vasoconstriction, per se. Intra-
brachial infusion of ET-1 at 0.5 ng/min had no effect on
forearm blood flow in healthy volunteers [21]. This dose
can be expected to increase the ET-1 plasma level in the
forearm by 2 to 4 pmol/L, which approximates the differ-
ences in ET-1 plasma concentration between control and
Tx patients in our study.
We observed differences in the vascular responsive-
ness to ET-1 and ET receptor antagonists between hy-
pertensive and normotensive renal transplant recipients.
Hypertensive patients showed a higher vascular sensitiv-
ity to exogenously administered ET-1 than normotensive
patients. Similar observations have been reported in pa-
tients with essential hypertension [13, 22]. Surprisingly,
the increased vascular sensitivity to ET-1 in hypertensive
patients was not associated with an increase in ET-1–
mediated arteriolar tone in this group. In fact, the vascu-
lar responses to ET receptor blockade were significantly
reduced in Hyper-Tx (whereas responses of Normo-Tx
were mostly at control level). These differences cannot
be explained by ET receptor down-regulation because
the sensitivity to exogenous ET-1 in Hyper-Tx was even
increased. Potential confounding factors like kidney func-
tion [14, 19], intake of statins [23], as well as kind and
plasma level of calcineurin inhibitors were excluded by
our matching of patients. To estimate the vascular ET-1
production in the forearm we have calculated the ratio of
ET-1–mediated vascular tone (maximum effect of unse-
lective ET receptor blockade) to ET- receptor sensitivity
(maximum effect of ET-1 itself) for each group. As this ra-
tio was significantly reduced in Hyper-Tx compared with
Normo-Tx we hypothesize a reduced vascular production
of ET-1 in Hyper-Tx. However, further experiments are
needed to verify this hypothesis. Furthermore, we cannot
fully rule out that antihypertensive medication may have
influenced the pattern of vascular responses in Hyper-Tx.
In this respect, the time between withdrawal of antihyper-
tensive medication and forearm blood flow studies may
have been too short for complete washout of drugs with
long half-lives. However, all Hyper-Tx patients experi-
enced an increase in blood pressure after withdrawal of
antihypertensives, and had moderate hypertension at the
time of FBF measurements. We therefore conclude that
endogenous ET-1 does not substantially contribute to the
constrictor tone of forearm resistance vessels in Hyper-
Tx.
Hypertensive patients had a lower baseline NO-
mediated vascular tone than normotensive patients. This
reduced baseline NO may be an important factor con-
tributing to hypertension in Hyper-Tx. Possible expla-
nations for the coincidence of low baseline NO and
increased sensitivity to ET-1 in Hyper-Tx include mod-
ulating effects of NO on ET receptors. Based on their
in vitro studies Wiley et al [24] suggested that NO was
able to reverse ET-1–induced vasoconstriction by direct
interaction with the ET receptor.
By plotting the individual maxima of vascular response
to L-NMMA (NO-mediated vascular tone) against the
maxima of vascular response to BQ123/788 (ET-1–
mediated vascular tone) we can demonstrate that both
NO- and ET-1–mediated vascular tone are reduced in
Hyper-Tx compared with Normo-Tx (Fig. 5). This find-
ing argues against the assumption that in hypertensive pa-
tients the vascular balance between NO and ET-1 might
be shifted toward the latter.
Both groups of renal transplant recipients showed an
equal impairment of vascular response to ACH compared
with control, indicating endothelial dysfunction. Similar
results have been reported in the literature [7, 25, 26].
CONCLUSION
Kidney transplantation with concomitant calcineurin
inhibitor–based immunosuppression is not associated
with a general increase in ET-1–mediated vascular tone.
Moreover, in the forearm circulation of hypertensive re-
nal transplant recipients the vascular endothelin system
is not overactive, but suppressed. In these patients re-
duced baseline NO may contribute to hypertension. Our
results, however, do not fully exclude a role for ET-1 in
post-transplant hypertension because our findings were
obtained in the forearm circulation and did not consider
renal effects of ET-1. Moreover, endothelin antagonists
may influence vascular and cardiac remodeling, as well
as chronic allograft rejection, which we have not tested.
Long-term studies using systemic doses of endothelin an-
tagonists are required to clarify these issues.
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